

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Boan Biotech**  
**博安生物**

**Shandong Boan Biotechnology Co., Ltd.**

**山东博安生物技术股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6955)**

**ANNOUNCEMENT**

**(1) UNUSUAL MOVEMENT IN TRADING VOLUME**

**AND**

**(2) DENOSUMAB (60MG) APPROVED FOR MARKETING IN BOLIVIA**

**(1) UNUSUAL MOVEMENT IN TRADING VOLUME**

The board of directors (the “**Board**”) of the Company noted the increase in trading volume of the shares of the Company (the “**H Shares**”) on 9 January 2026. Having made such enquiry with respect to the Company as may be reasonable in the circumstances, the Board confirms that, save as disclosed below, it is not aware of (i) any reasons for such movement in trading volume; (ii) any information which must be announced to avoid a false market in the Company’s securities; or (iii) any inside information that needs to be disclosed under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board has been notified by its controlling shareholder, Luye Pharma Group Ltd. (“**Luye Pharma**”, together with its subsidiaries, the “**Luye Pharma Group**”), that on 12 December 2025, Luye Geneora Holding Limited (the “**Issuer**”), a wholly-owned subsidiary of Luye Pharma, issued certain exchangeable preference shares (the “**Exchangeable Preference Shares**”). The Exchangeable Preference Shares entitle the holders thereof to exchange such shares into existing H Shares of the Company held by the Luye Pharma Group. For further details of the transaction and the Exchangeable Preference Shares, please refer to the announcements of Luye Pharma dated 21 November 2025 and 12 December 2025, respectively (collectively the “**Announcements**”).

As disclosed in the Announcements, Luye Pharma and the Issuer have agreed that following the issue of the Exchangeable Preference Shares, they will procure the transfer of 100,486,431 H Shares into a designated custodian account of the Issuer. Such transfer is to ensure that the Issuer is able to satisfy its obligations to deliver H Shares upon the exercise of the exchange rights attaching to the Exchangeable Preference Shares. To comply with such agreement, on 9 January 2026, the Luye Pharma Group arranged for the on-market transfer by Shandong Luye Pharmaceutical Co., Ltd. (山东绿叶制药有限公司), a wholly-owned subsidiary of Luye Pharma, of 50,000,000 H Shares to the Issuer.

As further disclosed in the Announcements, the Exchangeable Preference Shares are exchangeable into an aggregate of 100,486,431 H Shares. The Luye Pharma Group has confirmed to the Board that it will arrange further transfers of H Shares to the Issuer in accordance with the terms of the subscription agreement related to the Exchangeable Preference Shares.

The Board also confirms that there are no negotiations or agreements relating to intended acquisitions or realizations which are discloseable under Rule 13.23 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), and neither is the Board aware of any matter discloseable under the general obligation imposed by Rule 13.09 of the Listing Rules, which is or may be of a price-sensitive nature.

The disclosure under the above paragraph (1) related to unusual movement in trading volume of the H Shares is made by the order of the Company pursuant to Rule 13.10 of the Listing Rules, to which the Board collectively and individually accepts responsibility for the accuracy.

## **(2) DENOSUMAB (60MG) APPROVED FOR MARKETING IN BOLIVIA**

The Board announces that its in-house-developed denosumab injection (60mg), code-named BA6101, has been approved for marketing by the Agencia Estatal de Medicamentos y Tecnologías en Salud (AGEMED) in Bolivia.

BA6101 is a biosimilar to the reference product Prolia®, which is widely used globally for the treatment of osteoporosis. BA6101 shares the same indications as the reference product. Developed under the Company’s global R&D strategy, BA6101 is planned to be commercialized in multiple countries and regions worldwide. In 2022, BA6101 was approved for marketing in China under the trade name 博优倍®, becoming the first locally-developed denosumab injection. Currently, the marketing authorization application for BA6101 in the United Kingdom is under regulatory review, and the Company plans to submit marketing authorization applications in Europe, the United States (the “U.S.”), Japan, and other jurisdictions.

The development of BA6101 has strictly followed the relevant guidelines for biosimilars in China, the U.S., the European Union, and Japan. Its overall similarity to the reference product has been established by evidence from a series of analytical, non-clinical, human pharmacokinetic and clinical studies. In particular, BA6101 has been shown to be highly similar to the reference product in terms of quality, safety, and efficacy, with no clinically meaningful differences. In addition, BA6101 is manufactured in accordance with the highest international standards to ensure consistent quality for overseas markets.

The Company will collaborate with a partner to commercialize BA6101 in Bolivia, improving local access to denosumab and providing an additional treatment option for patients. In addition to Bolivia, the Company has entered into strategic partnerships for the commercialization of BA6101 in Brazil and other Latin American markets, as well as in the U.S., Southeast Asia, and the Hong Kong and Macao Special Administrative Regions of China. The Company will accelerate its internationalization strategy, offering high-quality biologics from China, including BA6101, to address the unmet needs of patients around the world.

The disclosure under the above paragraph (2) related to Denosumab (60mg) is made by the Company on a voluntary basis.

By Order of the Board  
**Shandong Boan Biotechnology Co., Ltd.**  
**Jiang Hua**  
*Chairlady, Chief Executive Officer and  
Executive Director*

Yantai, the People's Republic of China, 11 January 2026

*As at the date of this announcement, the executive directors of the Company are Ms. Jiang Hua, Dr. Dou Changlin and Mr. Wang Shenghan; the non-executive directors of the Company are Mr. Liu Yuanchong, Ms. Li Li and Mr. Li Shixu; and the independent non-executive directors of the Company are Professor Shi Luwen, Mr. Dai Jixiong and Dr. Yu Jialin.*